Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?

With inavolisib’s pivotal front-line win Roche reckons it can knock out Novartis’s Piqray.

But the FDA’s investigation looks like worse news for autoimmune disease than oncology.

Pelabresib’s Manifest-2 trial yields mixed data, but the bad part could render the whole unpalatable.

Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.

Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer. 

Ikena is savaged in a bear market after reporting zero remissions in a dose-escalation trial of its lead asset.

The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.

The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.